Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz-Ares; Mikhail Dvorkin; Yuanbin Chen; Niels Reinmuth; Katsuyuki Hotta; Dmytro Trukhin; Galina Statsenko; Maximilian J Hochmair; Mustafa Özgüroğlu; Jun Ho Ji; Oleksandr Voitko; Artem Poltoratskiy; Santiago Ponce; Francesco Verderame; Libor Havel; Igor Bondarenko; Andrzej Kazarnowicz; György Losonczy; Nikolay V Conev; Jon Armstrong; Natalie Byrne; Norah Shire; Haiyi Jiang; Jonathan W Goldman; Emilio Batagelj; Ignacio Casarini; Anea Viviana Pastor; Susana Noemi Sena; Juan Jose Zarba; Otto Burghuber; Sylvia Hartl; Maximilian J Hochmair; Bernd Lamprecht; Michael Studnicka; Luis Alberto Schlittler; Fabricio Augusto Martinelli de Oliveira; Aknar Calabrich; Gustavo Colagiovanni Girotto; Peo Dos Reis; Carlos Fausto Nino Gorini; Peo Rafael Martins De Marchi; Clarissa Serodio da Rocha Baldotto; Claudia Sette; Mauro Zukin; Nikolay V Conev; Assen Dudov; Rumyana Ilieva; Krassimir Koynov; Rositsa Krasteva; Ivan Tonev; Spartak Valev; Violetka Venkova; Minghong Bi; Chengshui Chen; Yuan Chen; Zhendong Chen; Jian Fang; Jifeng Feng; Zhigang Han; Jie Hu; Yi Hu; Wei Li; Zongan Liang; Zhong Lin; Rui Ma; Shenglin Ma; Kejun Nan; Yongqian Shu; Kai Wang; Mengzhao Wang; Gang Wu; Nong Yang; Zhixiong Yang; Helong Zhang; Wei Zhang; Jun Zhao; Yanqiu Zhao; Caicun Zhou; Jianying Zhou; Xiangdong Zhou; Libor Havel; Vitezslav Kolek; Leona Koubkova; Jaromir Roubec; Jana Skrickova; Milada Zemanova; Christos Chouaid; Werner Hilgers; Hervé Lena; Denis Moro-Sibilot; Gilles Robinet; Pierre-Jean Souquet; Jürgen Alt; Helge Bischoff; Christian Grohe; Eckart Laack; Susanne Lang; Jens Panse; Niels Reinmuth; Christian Schulz; Krisztina Bogos; Eszter Csánky; Anea Fülöp; Zsolt Horváth; Judit Kósa; Ibolya Laczó; György Losonczy; Gábor Pajkos; Zsuzsanna Pápai; Zsolt Pápai Székely; Veronika Sárosi; Attila Somfay; Éva Somogyiné Ezer; Anás Telekes; Jair Bar; Maya Gottfried; Norman Isaac Heching; Alona Zer Kuch; Roberta Bartolucci; Anna Cecilia Bettini; Angelo Delmonte; Marina Chiara Garassino; Mauro Minelli; Fausto Roila; Francesco Verderame; Shinji Atagi; Koichi Azuma; Hisatsugu Goto; Koichi Goto; Yu Hara; Hidetoshi Hayashi; Toyoaki Hida; Katsuyuki Hotta; Kenya Kanazawa; Shintaro Kanda; Young Hak Kim; Shoichi Kuyama; Tadashi Maeda; Masahiro Morise; Yasuharu Nakahara; Makoto Nishio; Naoyuki Nogami; Isamu Okamoto; Haruhiro Saito; Masahiro Shinoda; Shigeki Umemura; Tatsuya Yoshida; Niels Claessens; Robin Cornelissen; Lizza Heniks; Jeroen Hiltermann; Egbert Smit; Agnes Staal van den Brekel; Andrzej Kazarnowicz; Dariusz Kowalski; Slawomir Mańdziuk; Robert Mróz; Marek Wojtukiewicz; Tudor Ciuleanu; Doina Ganea; Anei Ungureanu; Mikhail Dvorkin; Alexander Luft; Vladimir Moiseenko; Artem Poltoratskiy; Dina Sakaeva; Alexey Smolin; Galina Statsenko; Alexander Vasilyev; Lyubov Vladimirova; Igor Anasina; Jozef Chovanec; Pavol Demo; Robert Godal; Peter Kasan; Marian Stresko; Michal Urda; Eun Kyung Cho; Jun Ho Ji; Joo-Hang Kim; Sang-We Kim; Gyeong-Won Lee; Jong-Seok Lee; Ki Hyeong Lee; Kyung Hee Lee; Yun Gyoo Lee; Maria Amelia Insa Molla; Manuel Domine Gomez; Juan Ignacio Delgado Mingorance; Dolores Isla Casado; Marta Lopez Brea; Margarita Majem Tarruella; Teresa Morán Bueno; Alejano Navarro Mendivil; Luis Paz-Ares Rodríguez; Santiago Ponce Aix; Maria Rosario Garcia Campelo; Gee-Chen Chang; Yen-Hsun Chen; Chao-Hua Chiu; Te-Chun Hsia; Kang-Yun Lee; Chien-Te Li; Chin-Chou Wang; Yu-Feng Wei; Shang-Yin Wu; Ahmet Alacacıoğlu; Irfan Çiçin; Ahmet Demirkazik; Mustafa Erman; Tuncay Göksel; Mustafa Özgüroğlu; Hryhoriy Adamchuk; Igor Bondarenko; Oleksii Kolesnik; Anna Kryzhanivska; Yuriv Ostapenko; Serhii Shevnia; Yaroslav Shparyk; Dmytro Trukhin; Grygorii Ursol; Nataliia Voitko; Oleksandr Voitko; Ihor Vynnychenko; Sunil Babu; Yuanbin Chen; Anne Chiang; Winston Chua; Shaker Dakhil; Afshin Dowlati; Jonathan W Goldman; Basir Haque; Rodney Jamil; Jeanna Knoble; Shailena Lakhanpal; Kailhong Mi; Petros Nikolinakos; Steven Powell; Helen Ross; Eric Schaefer; Jeffrey Schneider; Joseph Spahr; David Spigel; Joseph Stilwill; Christopher Sumey; Michael Williamson

doi:10.1016/s0140-6736(19)32222-6

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(19)32222-6 ◽

2019 ◽

Vol 394 (10212) ◽

pp. 1929-1939 ◽

Cited By ~ 172

Author(s):

Luis Paz-Ares ◽

Mikhail Dvorkin ◽

Yuanbin Chen ◽

Niels Reinmuth ◽

Katsuyuki Hotta ◽

...

Keyword(s):

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Extensive Stage ◽

Randomised Controlled ◽

First Line Treatment

Download Full-text

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30539-8 ◽

2021 ◽

Vol 22 (1) ◽

pp. 51-65 ◽

Cited By ~ 1

Author(s):

Jonathan W Goldman ◽

Mikhail Dvorkin ◽

Yuanbin Chen ◽

Niels Reinmuth ◽

Katsuyuki Hotta ◽

...

Keyword(s):

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Extensive Stage ◽

Randomised Controlled ◽

First Line Treatment

Download Full-text

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

The Lancet ◽

10.1016/s0140-6736(21)00228-2 ◽

2021 ◽

Vol 397 (10274) ◽

pp. 592-604 ◽

Cited By ~ 3

Author(s):

Ahmet Sezer ◽

Saadettin Kilickap ◽

Mahmut Gümüş ◽

Igor Bondarenko ◽

Mustafa Özgüroğlu ◽

...

Keyword(s):

Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Randomised Controlled ◽

First Line Treatment

Download Full-text

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30608-3 ◽

2017 ◽

Vol 18 (11) ◽

pp. 1454-1466 ◽

Cited By ~ 300

Author(s):

Yi-Long Wu ◽

Ying Cheng ◽

Xiangdong Zhou ◽

Ki Hyeong Lee ◽

Kazuhiko Nakagawa ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutation ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30167-6 ◽

2019 ◽

Vol 20 (7) ◽

pp. 924-937 ◽

Cited By ~ 202

Author(s):

Howard West ◽

Michael McCleod ◽

Maen Hussein ◽

Alessandro Morabito ◽

Achim Rittmeyer ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

First Line Treatment with Erlotinib Plus Bevacizumab or with Erlotinib Alone in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations (NEJ026): An Open-Label, Randomized, Multicenter, Phase 3 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3271416 ◽

2018 ◽

Author(s):

Haruhiro Saito ◽

Tatsuro Fukuhara ◽

Naoki Furuya ◽

Kana Watanabe ◽

Shunichi Sugawara ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Multicenter Phase ◽

First Line Treatment

Download Full-text

69 Afatinib versus gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations: results of the global, randomised, open-label, phase IIb trial LUX-Lung 7

Lung Cancer ◽

10.1016/s0169-5002(16)30086-1 ◽

2016 ◽

Vol 91 ◽

pp. S25

Author(s):

K.J. O'Byrne ◽

K. Park ◽

E. Tan ◽

L. Zhang ◽

V. Hirsh ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Abstract C122: A randomized, multicenter, open-label, phase 2 study of paclitaxel-carboplatin (PC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus PC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)

10.1158/1535-7163.targ-15-c122 ◽

2015 ◽

Author(s):

David Spigel ◽

Alexander Luft ◽

Rodryg Ramlau ◽

Mazen Khalil ◽

Joo-Hang Kim ◽

...

Keyword(s):

Stage Iv ◽

Small Cell ◽

Line Treatment ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

LBA2_PR Afatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7)

Annals of Oncology ◽

10.1093/annonc/mdv586.02 ◽

2015 ◽

Vol 26 ◽

pp. ix161 ◽

Cited By ~ 10

Author(s):

K. Park ◽

E.-H. Tan ◽

L. Zhang ◽

V. Hirsh ◽

K. O'Byrne ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(11)70184-x ◽

2011 ◽

Vol 12 (8) ◽

pp. 735-742 ◽

Cited By ~ 2256

Author(s):

Caicun Zhou ◽

Yi-Long Wu ◽

Gongyan Chen ◽

Jifeng Feng ◽

Xiao-Qing Liu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Egfr Mutation ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Treatment

Download Full-text

Squire: a Randomized, Multicenter, Open-Label, Phase III Study of Gemcitabine-Cisplatin (Gc) Chemotherapy Plus Necitumumab (Imc-11F8/Ly3012211) Vs Gc Alone in the First-Line Treatment of Patients (Pts) with Stage Iv Squamous Non-Small Cell Lung Cancer (Sq-Nsclc): Update on Key Subgroups

Annals of Oncology ◽

10.1093/annonc/mdu349.11 ◽

2014 ◽

Vol 25 ◽

pp. iv430 ◽

Cited By ~ 1

Author(s):

M.A. Socinski ◽

L. Paz-Ares ◽

A.V. Luft ◽

A. Szczesna ◽

T.E. Ciuleanu ◽

...

Keyword(s):

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text